The adaptive stroma joining the antiangiogenic resistance front

Journal of Clinical Investigation

Volumn 121, Issue 4, 2011, Pages 1244-1247

  Casanovas, Oriol ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADAPTATION; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; NOTE; OVERALL SURVIVAL; PERICYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEPTOR UPREGULATION; STROMA; TUMOR CELL; TUMOR MICROENVIRONMENT;

ADAPTATION, PHYSIOLOGICAL; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STROMAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953331016     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI46430     Document Type: Note

References (21)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273-286.
2. Boehm T, Folkman J, Browder T, O'Reilly MS. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390(6658):404-407.
3. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992-1000.
4. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008;14(20):6371-6375.
5. Kerbel RS, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001;20(1-2):79-86. (Pubitemid 34074682)
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932-936. (Pubitemid 43093958)
7. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
8. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci. 2009;30(12):624-630.
9. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res. 2009;15(16):5020-5025.
10. Crawford Y, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009;15(1):21-34.
11. Shojaei F, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25(8):911-920. (Pubitemid 47236916)
12. Shojaei F, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106(16):6742-6747.
13. Cascone T, et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest. 2011;121(4):1313-1328.
14. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111(9):1287-1295. (Pubitemid 36554699)
15. Helfrich I, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med. 2010;207(3):491-503.
16. Nisancioglu MH, Betsholtz C, Genove G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 2010;70(12):5109-5115.
17. Sennino B, et al. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res. 2009;69(10):4527-4536.
18. Lu C, et al. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010;9(3):176-182.
19. Nolan-Stevaux O, et al. Differential contribution to neuroendocrine tumorigenesis of parallel Egfr signaling in cancer cells and pericytes. Genes Cancer. 2010;1(2):125-141.
20. Miller VA, O'Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27(suppl):S18.
21. Kabbinavar FF, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28(suppl):Abstract 7526.